The global blood plasma derivatives market is growing mainly due to the increasing demand for plasma derived products. According to a recent study report published by the Market Research Future, The global blood plasma derivatives market is booming and expected to gain prominence over the forecast period. The market is forecasted to demonstrate a spectacular growth by 2023, surpassing its previous growth records in terms of value with a striking CAGR during the anticipated period (2017 – 2023).
Request Sample Copy
https://www.marketresearchfuture.com/sample_request/1325
Plasma is a fluid part of the blood that contains blood cells, and protein responsible for blood clotting. Plasma derivatives are obtained from specific plasma proteins by the process of fractionation. The derivatives are then solvent detergent-treated or heat-treated to kill certain viruses. The most common plasma derivative includes factor IX concentrate, factor VIII concentrate, anti-inhibitor coagulation complex (AICC), anti-thrombin III concentrate, immune globulins, Alpha 1-Proteinase inhibitor concentrate, albumin, and anti-thrombin III concentrate. Blood plasma derivative widely used clinically to treat various conditions such as hemophilia A, hemophilia B, HIV, hepatitis B, hepatitis C, thrombocytosis, and others.
Notably, rising demand for plasma derivative based therapies is the key factor driving the blood plasma derivatives market. According to a study published in the Journal of Blood Medicine in 2016, it is found that FIX replacement therapy which includes plasma-derived protein are successful in the reduction of disability, and bleeding from hemophilia B. Based on the prevalence rate, hemophilia and von willebrand disease (VWD) are the most common bleeding disorders in the Middle East and Africa.
Other factors such as, rising incidence of hemophilia, huge funding for research & development, technological advancements, and rising approval from regulatory bodies are also fuelling the market growth. According to the Centers for Disease Control and Prevention, it is found that Hemophilia A affects 1 in 5,000 male births i.e. around 400 babies are born with hemophilia A every year.
Despite these drivers, stringent reimbursement policies, safety concerns, and high cost of treatment is expected to decline the blood plasma derivatives market growth.
Global Blood Plasma Derivatives Market - Competitive Analysis
Grigols (Spain), Baxter International Inc. (US), Octapharma AG (Switzerland), CSL Limited (Australia), Kedrion S.p.A (Italy), Bain Capital, LLC (US), Biotest AG (Germany), Fusion Healthcare (India), SK Plasma Co., Ltd. (South Korea) are some of the prominent players at the forefront of competition in the blood plasma derivatives market and are profiled in MRFR Analysis.
The global blood plasma derivatives market is currently dominated by few players.
Grigols is one of them by holding a strong share in the market. The company’s stronghold is largely attributed to its innovative and sustainable products. Grigols aoperates in three major divisions i.e. Bioscience, Diagnostic and Hospital. On November 17, 2017 Grigols received FDA approval for a new genetic test used to detect alpha-1 antitrypsin deficiency. On November 11, 2013, Grifols acquired blood transfusion testing unit of Novartis AG for USD 1.68 billion. In the year 2016, Grifols has also acquired NAT (Nucleic Acid Testing) donor screening unit of Hologic for USD 1,850 million.
Baxter is also one of the leading players in blood plasma derivatives market. Baxter International Inc., the US based biopharmaceutical company, operates in two major segments, i.e. Hospital Products and Renal. Baxter’s product Bebulin (Factor IX Complex) is specifically used for the prevention, of hemorrhagic episodes in case of hemophilia B. Bebulin may carry a risk of transmitting infectious agents, such as viruses and, Creutzfeldt‐Jakob disease (CJD) agent.
On July 27, 2017, Baxter International Inc. completed the acquisition of Claris Injectables Limited for approximately USD 625 million. The main motive of acquisition is the expansion of generic pharmaceuticals.
Access Report Details @ https://www.marketresearchfuture.com/reports/blood-plasma-derivatives-market-1325
NOTE: Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact:
Akash Anand
Market Research Future
+1 646 845 9312
Email: [email protected]
Bovine Blood Plasma Derivatives covers different types of bovine blood plasma derivatives,and typically used in scientific research and industrial production.Thermo Fisher, GE Healthcare, Merck (Sigma-Aldrich), Moregate BioTech, Gemini, Atlanta Biologicals, Tissue Culture Biologicals and Bovogen are major players in this market.
Relying on blood supply from around the world, Thermo Fisher, GE Healthcare and Merck (Sigma-Aldrich) are the world’s three giants.
In 2017, Merck (Sigma-Aldrich) is the world leader with a market share of 22.62%North America plays an important role in global bovine blood plasma derivatives market, especially United States, which has great influence on the development of bovine blood plasma derivatives.
In Europe market, Germany, UK, France and Italy are playing significant roles, especially Germany, which has absolute predominance in Europe market.
The Asia-Pacific will take an increasing significant part in global bovine blood plasma derivatives market, due to the strong demand from China, India and Southeast Asian countries.Download FREE Sample of this Report @ https://www.grandresearchstore.com/report-sample/global-bovine-blood-plasma-derivatives-2019-2024-713According to this study, over the next five years the Bovine Blood Plasma Derivatives market will register a 4.3% CAGR in terms of revenue, the global market size will reach US$ 2080 million by 2024, from US$ 1680 million in 2019.
In particular, this report presents the global market share (sales and revenue) of key companies in Bovine Blood Plasma Derivatives business, shared in Chapter 3.This report presents a comprehensive overview, market shares, and growth opportunities of Bovine Blood Plasma Derivatives market by product type, application, key manufacturers and key regions and countries.This study considers the Bovine Blood Plasma Derivatives value and volume generated from the sales of the following segments:Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.Bovine SerumFBSBovine Serum AlbuminFibrinogenProtein IngredientOtherSegmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.Scientific ResearchIndustrial ProductionFeedOthersThis report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.AmericasUnited StatesCanadaMexicoBrazilAPACChinaJapanKoreaSoutheast AsiaIndiaAustraliaEuropeGermanyFranceUKItalyRussiaSpainMiddle East & AfricaEgyptSouth AfricaIsraelTurkeyGCC CountriesThe report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market.The key manufacturers covered in this report: Breakdown data in in Chapter 3.Thermo FisherGE HealthcareMerck (Sigma-Aldrich)Moregate BioTechGeminiAtlanta BiologicalsTissue Culture BiologicalsBovogenBiowestInternegociosRMBIOBiological IndustriesVWRCorningSeranaLanzhou MinhaiZhejiang Tianhang BiotechnologyExCell BioJin Yuan KangAmerican Protein CompanySonacIn addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole.
The Global Bovine Blood Plasma Derivatives Market research report offers accurate insights for the growth prospects of the Bovine Blood Plasma Derivatives market in the forecast years 2020-2027.
The report is an all-inclusive study of the Bovine Blood Plasma Derivatives market that offers the readers a better view of the current and emerging market trends through a thorough analysis of the market size, growth trends, supply and demand ratio, market share, sales network and distribution channels, and other key elements.Furthermore, the report is furnished with the current market scenario with regards to the COVID-19 pandemic.
The global public health emergency has disrupted the lives of everyone across the globe.
It has also had a substantial impact on the Bovine Blood Plasma Derivatives industry as global supply chains have been disrupted, and the financial scenario is tight.
The report assesses the initial and future impact of the pandemic on the market and its key segments to offer an accurate futuristic outlook for remuneration in a post-COVID-19 scenario.Get a sample copy of the report @ https://www.reportsanddata.com/sample-enquiry-form/3508Scope of the Market Report:The report offers a holistic overview of the Bovine Blood Plasma Derivatives industry that offers all the essential information.
Along with this, the report extensively studies the competitive landscape in the market and profiles the key players of the industry.The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies.
